Novartis (NYSE:NVS) Stock Rating Cut to “Sell” at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft lowered shares of Novartis (NYSE:NVS) from a hold rating to a sell rating in a research note released on Friday morning, Marketbeat Ratings reports.

Other analysts have also issued reports about the stock. Jefferies Financial Group restated a “neutral” rating on shares of Novartis in a research note on Thursday, July 23rd. Citigroup restated a “buy” rating on shares of Novartis in a report on Wednesday, July 22nd. Sanford C. Bernstein reissued a “neutral” rating on shares of Novartis in a report on Wednesday, July 22nd. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Novartis in a research report on Wednesday. Finally, Bank of America reissued a “buy” rating on shares of Novartis in a research report on Tuesday, September 8th. Six analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Novartis currently has a consensus rating of “Hold” and an average price target of $152.25.

Novartis Price Performance

Novartis stock opened at $160.67 on Friday. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 0.98. Novartis has a 52-week low of $122.57 and a 52-week high of $170.46. The firm has a market cap of $306.58 billion, a PE ratio of 30.66, a price-to-earnings-growth ratio of 2.97 and a beta of 0.41. The company’s 50 day moving average is $148.41 and its two-hundred day moving average is $151.80.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Tuesday, October 27th. The company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.25 by $0.21. Novartis had a return on equity of 41.04% and a net margin of 18.11%. The business had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.53 billion. During the same period last year, the firm earned $2.25 earnings per share. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. On average, research analysts expect that Novartis will post 9.02 EPS for the current fiscal year.

Institutional Trading of Novartis

Several large investors have recently bought and sold shares of the company. CPC Advisors LLC grew its holdings in Novartis by 4.6% in the second quarter. CPC Advisors LLC now owns 1,516 shares of the company’s stock worth $238,000 after purchasing an additional 66 shares during the period. Canopy Partners LLC raised its stake in Novartis by 1.9% during the third quarter. Canopy Partners LLC now owns 3,525 shares of the company’s stock valued at $503,000 after buying an additional 67 shares during the last quarter. Busey Bank boosted its holdings in Novartis by 2.8% in the third quarter. Busey Bank now owns 2,521 shares of the company’s stock worth $359,000 after acquiring an additional 69 shares in the last quarter. Moody National Bank Trust Division grew its stake in shares of Novartis by 4.2% in the second quarter. Moody National Bank Trust Division now owns 1,802 shares of the company’s stock worth $282,000 after acquiring an additional 72 shares during the last quarter. Finally, PFG Investments LLC raised its position in shares of Novartis by 1.8% in the 2nd quarter. PFG Investments LLC now owns 4,173 shares of the company’s stock worth $654,000 after purchasing an additional 72 shares during the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

Key Novartis News

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis received a Zacks Rank #2 (Buy), reflecting improved expectations for its earnings prospects. The upgrade could provide near-term support for the shares. Novartis Rating Upgrade to Buy
• Positive Sentiment: Zacks also identified NVS as a strong long-term momentum stock, highlighting favorable style and performance characteristics that may attract growth and momentum investors. Novartis Top Momentum Stock
• Positive Sentiment: Novartis’s third-quarter results exceeded consensus expectations, with earnings per share of $2.46 versus $2.25 expected and revenue of $15.03 billion versus $14.53 billion expected. Revenue increased 4.4% year over year, supporting the company’s fundamental outlook. Novartis Q3 2026 Earnings Call Transcript
• Neutral Sentiment: DZ Bank initiated coverage with a Hold rating, signaling a balanced view of Novartis’s earnings strength and valuation. DZ Bank Novartis Coverage
• Negative Sentiment: Deutsche Bank downgraded Novartis from Hold to Sell, adding direct analyst pressure to the stock and countering the more favorable Zacks assessment. Deutsche Bank Downgrades Novartis
• Negative Sentiment: Analysts reduced peak-sales forecasts for remibrutinib after a late-stage multiple-sclerosis trial met its primary endpoint but appeared weaker than expected. The development raises concerns about the drug’s ability to offset upcoming patent-related revenue pressure. Novartis Remibrutinib and Patent Cliff
• Negative Sentiment: Erste Group Bank forecast weaker earnings for Novartis, adding to concerns that future results may not match the company’s recent quarterly beat. Erste Group Predicts Weaker Novartis Earnings

About Novartis

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities span areas including cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix.

Novartis serves patients and healthcare providers in markets around the world.